<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250506065624N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-08-12</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Effect of spirulina algae supplementation on nutritional status, hormonal status, cardiometabolic indices and clinical symptoms in women with polycystic ovary syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Effect of spirulina (Arthrospira plantensis) supplementation on nutritional status, hormonal status, cardiometabolic indices and clinical symptoms in women with polycystic ovary syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>46</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/83398</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants will be randomly assigned to either the intervention or placebo group using simple randomization through the Random Allocation Software (RASS). This software will automatically generate a random allocation sequence in which each participant will have an equal probability (50%) of being assigned to one of the two groups. In this method, the allocation of each individual will be entirely independent of others, and the order of participant enrollment will not influence the randomization process.
To ensure allocation concealment, the random codes generated by the software will be placed in sealed, opaque, and sequentially numbered envelopes, to be opened in the order of participant enrollment. These codes will only indicate group designation (Group A or Group B), and both the investigators and participants will remain blinded to the actual content of the intervention (supplement or placebo) until data collection is complete. This procedure is intended to minimize allocation bias and enhance the internal validity of the study, Blinding description: In this study, in order to minimize bias and enhance the validity of the results, a double-blind design will be employed, whereby neither the participants nor the principal investigator will be aware of the group assignments (intervention or control). The blinding process will be implemented according to the following steps:
First, eligible participants will be randomly assigned to either the intervention or control group. To maintain impartiality, the allocation will be performed by an independent individual who will not be involved in data collection or data analysis. The intervention supplement and the placebo will be identical in appearance, color, size, odor, and packaging, and will be prepared by a pharmaceutical company. Each participant will receive the assigned product based on numerical coding (e.g., A and B). These codes will remain confidential with the individual responsible for blinding until the completion of data analysis.
All participants will receive standardized instructions on how to consume the supplement, without any knowledge of their group assignment. Furthermore, the researcher responsible for data collection and analysis will remain blinded to the group allocations throughout the study. After the data collection phase is complete, the codes will be unblinded and the data will be analyzed accordingly.
The use of this approach is expected to minimize the risk of both conscious and unconscious bias on the part of the researcher and the participants, thereby improving the internal validity of the study.</study_design>
      <phase>3</phase>
      <hc_freetext>polycystic ovary syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The spirulina supplementation, with a dose of 500 mg, will be taken three times daily with meals for better absorption over a period of 12 weeks, provided by (Goldspir Iran Company). Intervention 2: Control group: The maltodextrin supplement, with the same appearance and packaging as the spirulina supplement, will be taken three times daily with meals for better absorption over a period of 12 weeks, provided by (Goldspir Iran Company).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is there are not extra data more than results presented in our articles</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Niloofar Barani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Talash Female Dormitory, Tabriz University of Medical Sciences Entrance, Before Pishghadam Bridge, from Vali-Asr Hospital Side, Middle Beltway, Tabriz, Iran</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5163996937</zip>
        <telephone>+98 31 3444 9944</telephone>
        <email>nlfbrn79@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Vahideh Ebrahimzadeh Attari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Nutrition and Food Sciences, Attar Neishabouri Street, Golgasht Street, Tabriz, Iran</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5165665931</zip>
        <telephone>+98 41 3727 5552</telephone>
        <email>ebrahimzadehv@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women diagnosed with polycystic ovary syndrome (PCOS) based on physician assessment and the Rotterdam criteria
Age between 20 and 45 years
Body mass index (BMI) ranging from 25 to 35 kg/m²
Willingness to participate in the study</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Presence of hepatic, renal, cardiovascular diseases, diabetes mellitus, Cushing's syndrome, or hyperprolactinemia
History of allergy to algae or seafood products
Use of weight loss medications
Use of oral contraceptive pills (OCPs) for birth control
Pregnancy or lactation
Engagement in a regular exercise program
Adherence to a specific diet within the past three months
Use of any type of supplement (including nutritional or herbal) within the past three months
History of severe allergic reaction to a supplement or placebo
Use of tobacco, alcohol, or hookah</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E28.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Polycystic ovarian syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The spirulina supplementation, with a dose of 500 mg, will be taken three times daily with meals for better absorption over a period of 12 weeks, provided by (Goldspir Iran Company).</i_keyword>
      <i_keyword>Control group: The maltodextrin supplement, with the same appearance and packaging as the spirulina supplement, will be taken three times daily with meals for better absorption over a period of 12 weeks, provided by (Goldspir Iran Company)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Testosterone hormone. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: Blood samples for testosterone measurement will be collected after a 10 to 12-hour overnight fast. Following collection, the blood samples will be kept at room temperature for 30 minutes to allow clot formation. The samples will then be centrifuged at 3,000 rpm for 10 minutes. The separated serum will be aliquoted into specific microtubes and stored at –80°C until analysis. Serum hormone concentrations will be measured using high-sensitivity ELISA kits, and all samples will be analyzed in a single batch.</prim_outcome>
      <prim_outcome>Dehydroepiandrosterone sulfate hormone. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: Blood samples for Dehydroepiandrosterone sulfate measurement will be collected after a 10 to 12-hour overnight fast. Following collection, the blood samples will be kept at room temperature for 30 minutes to allow clot formation. The samples will then be centrifuged at 3,000 rpm for 10 minutes. The separated serum will be aliquoted into specific microtubes and stored at –80°C until analysis. Serum hormone concentrations will be measured using high-sensitivity ELISA kits, and all samples will be analyzed in a single batch.</prim_outcome>
      <prim_outcome>Estradiol (E2) hormone. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: Blood samples for estradiol measurement will be collected after a 10 to 12-hour overnight fast. Following collection, the blood samples will be kept at room temperature for 30 minutes to allow clot formation. The samples will then be centrifuged at 3,000 rpm for 10 minutes. The separated serum will be aliquoted into specific microtubes and stored at –80°C until analysis. Serum hormone concentrations will be measured using high-sensitivity ELISA kits, and all samples will be analyzed in a single batch.</prim_outcome>
      <prim_outcome>Progesterone hormone. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: Blood samples for progesterone measurement will be collected after a 10 to 12-hour overnight fast. Following collection, the blood samples will be kept at room temperature for 30 minutes to allow clot formation. The samples will then be centrifuged at 3,000 rpm for 10 minutes. The separated serum will be aliquoted into specific microtubes and stored at –80°C until analysis. Serum hormone concentrations will be measured using high-sensitivity ELISA kits, and all samples will be analyzed in a single batch.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Weight. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: Patients’ body weight will be measured using a Seca scale with an accuracy of 0.5 kg, while they are barefoot and wearing minimal clothing.</sec_outcome>
      <sec_outcome>Body mass index(BMI). Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: Body mass index (BMI) will be calculated using the formula weight (kg) divided by the square of height (m), i.e., weight (kg)/height (m)².</sec_outcome>
      <sec_outcome>Waist circumference. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: Waist circumference of the participants will be measured using a flexible measuring tape at the midpoint between the lower margin of the last palpable rib and the top of the iliac crest, following a normal expiration.</sec_outcome>
      <sec_outcome>Hip circumference (HC). Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: Hip circumference will be measured using a flexible measuring tape at the point of the greatest protrusion of the buttocks.</sec_outcome>
      <sec_outcome>Body composition. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: Body composition will be assessed using a Tanita body analyzer.</sec_outcome>
      <sec_outcome>Appetite. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: Appetite will be assessed using a five-point questionnaire based on a Likert scale (with a response range from 0 to 10), the validity and reliability of which have been previously established.</sec_outcome>
      <sec_outcome>Energy intake. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: To assess energy intake, a three-day food diary questionnaire will be completed by the participants. Upon completion of the questionnaire, the amount of each food item consumed will be calculated in grams, and the average three-day daily energy intake for each individual will be determined using the Nutritionist IV software.</sec_outcome>
      <sec_outcome>Macronutrients. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: To assess macronutrient intake, a three-day food diary questionnaire will be completed by the participants. Upon completion of the questionnaire, the amount of each food item consumed will be calculated in grams, and the average three-day macronutrients intake for each individual will be determined using the Nutritionist IV software.</sec_outcome>
      <sec_outcome>Micronutrients. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: To assess micronutrient intake, a three-day food diary questionnaire will be completed by the participants. Upon completion of the questionnaire, the amount of each food item consumed will be calculated in grams, and the average three-day micronutrients intake for each individual will be determined using the Nutritionist IV software.</sec_outcome>
      <sec_outcome>Fasting Blood Glucose. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: At the beginning and end of the study, after selecting eligible participants and grouping them, blood samples for measuring fasting blood glucose will be collected after a 10 to 12-hour overnight fast. After collection, the blood samples will be kept at room temperature for 30 minutes to allow clot formation, followed by centrifugation at 3,000 rpm for 10 minutes. The serum will be separated and aliquoted into specific microtubes and stored at –80°C until analysis and all samples will be analyzed in a single batch.</sec_outcome>
      <sec_outcome>Insulin. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: At the beginning and end of the study, after selecting eligible participants and grouping them, blood samples for measuring insulin indices will be collected after a 10 to 12-hour overnight fast. After collection, the blood samples will be kept at room temperature for 30 minutes to allow clot formation, followed by centrifugation at 3,000 rpm for 10 minutes. The serum will be separated and aliquoted into specific microtubes and stored at –80°C until analysis. Serum insulin concentration will be measured using high-sensitivity ELISA kits, and all samples will be analyzed in a single batch.</sec_outcome>
      <sec_outcome>Total Cholesterol. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: At the beginning and end of the study, after selecting eligible participants and grouping them, blood samples for measuring total cholesterol will be collected after a 10 to 12-hour overnight fast. After collection, the blood samples will be kept at room temperature for 30 minutes to allow clot formation, followed by centrifugation at 3,000 rpm for 10 minutes. The serum will be separated and aliquoted into specific microtubes and stored at –80°C until analysis and all samples will be analyzed in a single batch.</sec_outcome>
      <sec_outcome>Triglyceride. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: At the beginning and end of the study, after selecting eligible participants and grouping them, blood samples for measuring triglyceride will be collected after a 10 to 12-hour overnight fast. After collection, the blood samples will be kept at room temperature for 30 minutes to allow clot formation, followed by centrifugation at 3,000 rpm for 10 minutes. The serum will be separated and aliquoted into specific microtubes and stored at –80°C until analysis and all samples will be analyzed in a single batch.</sec_outcome>
      <sec_outcome>High-Density Lipoprotein Cholesterol (HDL-C). Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: At the beginning and end of the study, after selecting eligible participants and grouping them, blood samples for measuring High-Density Lipoprotein Cholesterol will be collected after a 10 to 12-hour overnight fast. After collection, the blood samples will be kept at room temperature for 30 minutes to allow clot formation, followed by centrifugation at 3,000 rpm for 10 minutes. The serum will be separated and aliquoted into specific microtubes and stored at –80°C until analysis and all samples will be analyzed in a single batch.</sec_outcome>
      <sec_outcome>Low-Density Lipoprotein Cholesterol (LDL-C). Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: At the beginning and end of the study, after selecting eligible participants and grouping them, blood samples for measuring Low-Density Lipoprotein Cholesterol will be collected after a 10 to 12-hour overnight fast. After collection, the blood samples will be kept at room temperature for 30 minutes to allow clot formation, followed by centrifugation at 3,000 rpm for 10 minutes. The serum will be separated and aliquoted into specific microtubes and stored at –80°C until analysis and all samples will be analyzed in a single batch.</sec_outcome>
      <sec_outcome>Systolic Blood Pressure. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: The systolic blood pressure of the participants will be measured by the investigator using a mercury sphygmomanometer.</sec_outcome>
      <sec_outcome>Diastolic Blood Pressure. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: The diastolic blood pressure of the participants will be measured by the investigator using a mercury sphygmomanometer.</sec_outcome>
      <sec_outcome>Hirsutism. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: To assess hirsutism, the modified Ferriman-Gallwey (mFG) score will be used, in which hair growth in 9 different body areas (such as the face, chest, and abdomen) will be evaluated on a scale from 0 to 4, and the total score will determine the severity of hirsutism. Additionally, for the overall evaluation of clinical symptoms related to PCOS, the modified PCOS Health-Related Quality of Life Questionnaire (MPCOSQ) will be used.</sec_outcome>
      <sec_outcome>Acne. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: To assess acne, the Global Acne Grading System (GAGS) will be used, which evaluates the severity of acne in different body areas based on the type of lesions (such as comedones, papules, pustules, and nodules) and assigns scores accordingly. Additionally, for the overall evaluation of clinical symptoms related to PCOS, the modified PCOS Health-Related Quality of Life Questionnaire (MPCOSQ) will be used.</sec_outcome>
      <sec_outcome>Menstrual cycle. Timepoint: At baseline and after 12 weeks of Spirulina supplementation. Method of measurement: To assess the menstrual cycle, the modified PCOS-related Health-Related Quality of Life questionnaire (MPCOSQ) will be used in the study.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-06-30</approval_date>
        <contact_name>Ethics Committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Talash Girls' Dormitory, Entrance of Tabriz University of Medical Sciences, Before Pishghadam Bridge, from Vali-Asr Hospital Direction, Middle Ring Road, Tabriz, Iran Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
